Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2021-22 | Page 113

# Consolidated Statement of Financial Position

**Reporting Period:** As at June 30, 2022  
**Reporting Currency & Multiplier:** BDT (Amount in Taka) | **Scale Multiplier:** 1.0

### Consolidated Statement of Financial Position

| Particulars | Notes | June 30, 2022 | June 30, 2021 |
| --- | --- | --- | --- |
| ASSETS |  |  |  |
| Non-Current Assets |  | 47,728,777,460 | 38,475,237,847 |
| Property, Plant and Equipment- Carrying Value | 4 | 41,760,330,727 | 36,211,375,594 |
| Right-of-use Assets 4(a) |  | 618,891,376 | 319,884,849 |
| Intangible Assets | 5 | 4,562,988,045 | 1,380,693,809 |
| Deferred Tax Asset |  | 88,640,228 | - |
| Goodwill | 6 | 674,570,185 | 546,691,213 |
| Other Investments | 7 | 23,356,899 | 16,592,382 |
| Current Assets |  | 18,419,258,282 | 13,770,846,179 |
| Inventories | 8 | 10,405,295,079 | 7,142,863,477 |
| Spares & Supplies | 9 | 718,797,256 | 661,722,724 |
| Accounts Receivable | 10 | 3,142,817,194 | 2,873,844,874 |
| Loans, Advances and Deposits | 11 | 2,787,039,904 | 2,416,948,496 |
| Advance Income Tax |  | 196,635,028 | - |
| Cash and Cash Equivalents | 12 | 1,168,673,821 | 675,466,608 |
| TOTAL ASSETS |  | 66,148,035,742 | 52,246,084,026 |
| EQUITY AND LIABILITIES |  |  |  |
| Equity Attributable to the Owners of the Company |  | 40,600,497,817 | 37,030,558,202 |
| Issued Share Capital | 13 | 4,461,120,890 | 4,461,120,890 |
| Share Premium |  | 5,269,474,690 | 5,269,474,690 |
| Excess of Issue Price over Face Value of GDRs |  | 1,689,636,958 | 1,689,636,958 |
| Capital Reserve on Merger |  | 294,950,950 | 294,950,950 |
| Revaluation Surplus |  | 1,116,896,688 | 1,121,824,646 |
| Unrealized Gain/(Loss) |  | 20,531,723 | 13,767,206 |
| Retained Earnings |  | 27,747,885,918 | 24,179,782,862 |
| Non-Controlling Interest | 14 | 4,035,506,641 | 334,306,627 |
| TOTAL EQUITY |  | 44,636,004,458 | 37,364,864,829 |
| Non-Current Liabilities |  | 8,776,099,208 | 5,531,540,789 |
| Long Term Borrowings-Net of Current Maturity | 15 | 3,454,188,843 | 1,206,717,094 |
| Liability for Gratuity, Pension and WPPF & Welfare Funds | 16 | 2,785,072,661 | 2,335,257,766 |
| Deferred Tax Liability |  | 2,536,837,704 | 1,989,565,929 |
| Current Liabilities and Provisions |  | 12,735,932,076 | 9,349,678,408 |
| Short Term Borrowings | 17 | 6,850,550,319 | 5,023,181,128 |
| Long Term Borrowings-Current Maturity | 18 | 2,065,962,471 | 1,401,406,013 |
| Creditors and Other Payables | 19 | 2,465,039,217 | 1,965,048,180 |
| Accrued Expenses | 20 | 1,166,881,586 | 619,399,363 |
| Dividend Payable / Unclaimed Dividend | 21 | 88,049,428 | 118,137,390 |
| Income Tax Payable |  | 99,449,055 | 222,506,334 |
| TOTAL EQUITY AND LIABILITIES |  | 66,148,035,742 | 52,246,084,026 |